Apr 3, 2018 · 21m · top-founders
983 200 People Have Paid Him $2k To Live Forever
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Nathan Latka interviews Forever Labs co-founder and CEO Steven Klausnitzer to explore how his Y Combinator-backed startup banks youthful stem cells to combat aging, detailing the company's partner-physician business model, clinical trial landscape, and revenue metrics.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 33% of the talking time here. How this is scored →
Nathan as informed peer 3.2 Guest teaching 4.2 Guest disagreement 1.3 Nathan pushing back 2.2
speaking balance: gold is Nathan, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 8:35 Pushing back against the vanity signaling premise
Steven rejects Nathan's claim that customers only purchase the service for brunch bragging rights, stating the underlying regenerative medicine is far more significant.
Hardest push from Nathan ▶ 16:14 Challenging longevity's impact on overpopulationNathan directly presses Steven on whether enabling extreme lifespans exacerbates unsustainable population growth.
Biggest teaching moment ▶ 9:28 Explaining the cellular limitations of older patientsSteven corrects Nathan's assumption about using an 80-year-old's existing tissue, detailing why aged stem cells fail to culture and why young preservation is necessary.
Nathan holds their own ▶ 12:39 Deconstructing unit economics on the flyNathan takes the raw user count and rapidly models the upfront cash injection against the long-term annual subscription run rate.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Nathan as informed peer | Guest teaching | Guest disagreement | Nathan pushing back | Why |
|---|---|---|---|---|---|---|
| Introducing Steven Klausnitzer and Forever Labs | 3 | 4 | 1 | 2 | Nathan probes Steven on why Forever Labs has not yet exploded into mainstream celebrity status and explores the onboarding process in real time. Steven educates Nathan on why credentialed surgeons across nine states are required rather than setting up standard clinics. | |
| Procedure Mechanics, Cryopreservation, and Pricing Plans | 3 | 5 | 1 | 2 | Nathan asks visceral questions about pain, scarring, and drilling during the bone extraction. Steven clarifies that the aspiration process is virtually painless compared to biopsies and details the cryogenic storage process. | |
| Clinical Applications and Therapeutic Potential | 2 | 6 | 2 | 3 | Nathan cynically suggests customers are purely buying social status to brag to their friends. Steven rejects the superficial premise, explaining concrete clinical trial data where elderly patients failed to heal because their older stem cells were no longer viable. | |
| Founding Origin, Mouse Research, and Early Traction | 6 | 3 | 1 | 1 | Steven shares the scientific origin story involving mouse lifespan studies and co-founding the business. Nathan demonstrates business acumen by calculating unit economics and recurring revenue from the 200 customer milestone. | |
| Longevity Moonshot, Escape Velocity, and Ethical Views | 3 | 5 | 2 | 4 | Nathan presses Steven on the societal ethics of extreme longevity and global overpopulation. Steven addresses the concern by using a car maintenance analogy to illustrate health maintenance versus disease treatment. | |
| Sponsor Break: User Analytics with Hotjar | 2 | 2 | 1 | 1 | After an ad read, Nathan moves through the standard 'Famous Five' rapid-fire questions, closing with a recap of the business model and funding numbers. |
Statements from this episode (14)
Klausnitzer: Over 500 clinical trials use banked stem cells for aging diseases
“And there are over 500 clinical trials that are using the cells we store to treat age related diseases.”
Forever Labs partners with local surgeons instead of opening physical clinics
“We have credentialed physicians in nine states. So we don't open offices. What I do is I go out and I find the best doctors in every market. And these tend to be for us, orthopedic surgeons and plastic surgeons.”
Forever Labs charges $2,500 for extraction and $250 annually for storage
“It's 2500 dollars for the procedure. And then it's 250 dollars a year to store your stuff.”
Customers flying from SF to Michigan prompted Forever Labs' coastal expansion
“We started in Michigan, but then what happened is we had people flying out from San Francisco to Michigan to have the procedure done. And we realized very quickly that we needed to expand and our second market was San Francisco.”
Customers rate Forever Labs bone marrow extraction pain at two of ten
“I say, on a scale of one to 10, you know, what would you rate this if one is no pain and 10 is painful?
And we are averaging a two.”
Forever Labs co-founder grew more stem cells outside his body than inside
“My co-founder, Dr. Katakowski has grown more of his own stem cells outside of his body than he has in his body right now.”
Klausnitzer: Stem cell therapies for heart disease and stroke are in Phase 3
“And some of these are in phase three, cardiovascular disease and stroke are in phase three.”
Johns Hopkins researchers replaced heart attack scar tissue using banked stem cells
“At Johns Hopkins, they took these bone marrow derived mesenchymal stem cells, that same ones we store for you. And they grew them and introduced them into the damaged area of a person's heart after they had a heart attack. And they were able to grow healthy ti…”
Reintroducing young stem cells extended older mice lifespans by up to 20%
“Two other groups had since done that same work and had shown that the mice lived about 16 to 20% longer with just one reintroduction.”
Forever Labs reached 200 paying clients across nine states
“So we're in, like, we're in nine states. We have over 200, or no, we're just about at our 200th client right now.”
Steven Klausnitzer plans to intravenously reintroduce his banked 38-year-old stem cells
“So I want, I'm going to take my thirty-eight-year-old cells when I'm, I think, about 45 years old. I'm going to grow them, and I'm going to start reintroducing them intravenously. And not to treat any specific disease or just to reconstitute my stem cell.”
Coastal customers bank stem cells for longevity, Midwest customers for disease treatment
“If we're in Michigan or North Carolina it's a much more pragmatic market. People signing up there are signing up in order to treat perhaps a family disease. They may have a family history of cardiovascular disease. Or osteoarthritis or rheumatoid arthritis, wh…”
Klausnitzer argues reactive disease treatment is inferior to proactive cellular maintenance
“We can do that now at the cellular level. So that's what I'm talking about as far as health maintenance. So we're a disease treatment society. It's ridiculous. We wait till our body breaks down and then we try to get it back to homeostasis. It's silly, really,…”